The U.S. atherectomy devices market size is expected to reach USD 626.1 million by 2025 expanding at a CAGR of 6.6%, according to a new report by Grand View Research, Inc. The regional market is expected to witness lucrative growth due to the rising prevalence of target diseases and preference for endovascular procedures. Moreover, rising demand for minimally invasive procedure will boost the market growth. Such procedures are less painful and allow quicker recovery than invasive procedures.
Other advantages, such as higher patient satisfaction owing to fewer incision wounds, few post-surgical complications, and low mortality rates, are also driving the atherectomy devices market growth. Technological advancements allowing early diagnosis are also likely to augment the market growth in the near future. For instance, in January 2017, Medtronic received CE mark approval for HawkOne directional atherectomy system for treating patients suffering from Peripheral Artery Disease (PAD).
To request a sample copy or view summary of this report, click the link below:
Further key findings from the study suggest:
Adoption of atherectomy increased sharply in the past due to increased reimbursement for the procedure. According to Elsevier Inc., there was a rise in atherectomy volume for Medicare beneficiaries to 76% in 2011–2015
Directional atherectomy devices accounted for the largest share of the market in 2017 as the device exhibited 95% successful removal of lesions and 94% of patients did not exhibit adverse effects
Office-Based Labs (OBLs) is anticipated to be the fastest-growing segment in the forecast period due to a greater number of Peripheral Vascular Interventional (PVI) procedures being performed in this setting
In addition, lesser number of complications and follow-up procedures lowers the cost and increases the adoption of new technologies delivering better health outcomes, which is anticipated to propel the market growth in the coming years
Several ongoing trials and their positive results facilitate penetration of novel technologies. For instance, in March 2017, Cardiovascular Systems, Inc. enrolled for its latest clinical trial, ECLIPSE, which was perceived to be the largest trial conducted to study coronary atherectomy
Some of the key companies are Spectranetics Corp.; Boston Scientific Corp.; Cardinal Health, Inc.; Straub Medical AG; Terumo Medical Corp.; Cardiovascular Systems, Inc.; Medtronic PLC; Avinger, Inc.; ST. JUDE MEDICAL, Inc.
Grand View Research has segmented the U.S. atherectomy devices market on the basis of type and end use:
Atherectomy Devices Market Type (Revenue, USD Million, 2014 - 2025)
Atherectomy Devices Market End Use (Revenue, USD Million, 2014 - 2025)
Office-based Labs (OBLs)
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."